Analysis showed that PFS was better in the pirtobrutinib group compared with the bendamustine group, with 24-month PFS rates of 93.4% and 70.7%, respectively. More work will be needed to determine the ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...

For more than a century, people have considered Alzheimer's disease (AD) an irreversible illness. Consequently, research has focused on preventing or slowing it, rather than recovery. Despite billions ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Washington, D.C.: The Executive Board of the International Monetary Fund (IMF) has formally completed its review of the Short-Term Liquidity Line (SLL) on December 15th. The Review concluded that the ...

Pirtobrutinib, a highly selective, noncovalent Bruton’s tyrosine kinase inhibitor (BTKi), shows substantial improvements in progression-free survival over the chemotherapy regimen of bendamustine plus ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

All websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings ...

For many older homeowners, home equity has become one of the most valuable financial resources they have. Case in point? U.S. homeowners held a collective $17.8 trillion in home equity as of mid-2025, ...

With high mortgage rates and home prices not much better, downsizing isn't very attractive to many older homeowners these days. Instead, reverse mortgages — which allow you to turn your existing home ...

Findings showed pirtobrutinib was noninferior to ibrutinib in both the pre-treated and intent-to-treat populations for the endpoint of ORR. Topline data were announced from a head-to-head phase 3 ...